mutations offered the fact that, as defined beneath, CLL therapy is based over the existence or absence of such mutations. The present consensus is, besides clonal mutations, subclonal mutations that has a variant allelic frequency starting from five to 10% (and so down below the brink of detection by regular molecular methods) could also be claime